Closed claims data explained: Benefits, limitations and commercial use cases
Know what closed payer claims can reveal about patient journeys, treatment persistence and the...
Know what closed payer claims can reveal about patient journeys, treatment persistence and the...
Most teams planning a total cost of care or burden of illness study assume the cost data will be...
Know what open claims data can reveal and when it’s the right starting point for research Adding...
Open claims and closed payer claims data are essential for understanding the status and activities...
Understanding mortality in taXonomy and the importance of post mortem activity This is the third...
A better way to measure healthcare costs in closed claims data This is the second post in our...
Capturing the true complexity of psoriasis in the real world Psoriasis is a common chronic...
As the new year begins, many patients refocus on weight management and long-term health goals. At...
Industry trends in ulcerative colitis research: a new path Ulcerative colitis is a chronic...
Alzheimer’s disease burden and the current therapy pipeline Alzheimer’s disease remains the leading...
We put the newest HealthVerity eXOs capabilities to the test on one of the most-watched questions in healthcare: who is starting GLP-1s, where they are and what happens next. Here is what the new features did and what the data revealed.